Mesenchymal stem cell therapy in patients with small bowel transplantation: single center experience.

World J Gastroenterol 2014 Jul;20(25):8215-20

Sait Murat Doğan, Selçuk Kılınç, Eyüp Kebapçı, Cem Tuğmen, Mustafa Ölmez, Cezmi Karaca, Organ Transplantation Center, SB Tepecik Teaching and Research Hospital, 35121 Izmir, Turkey.

Aim: To study the effects of mesenchymal stem cell (MSC) therapy on the prevention of acute rejection and graft vs host disease following small bowel transplantation.

Methods: In our transplantation center, 6 isolated intestinal transplants have been performed with MSC therapy since 2009. The primary reasons for transplants were short gut syndrome caused by surgical intestine resection for superior mesenteric artery thrombosis (n = 4), Crohn's disease (n = 1) and intestinal aganglionosis (n = 1). Two of the patients were children. At the time of reperfusion, the first dose of MSCs cultured from the patient's bone marrow was passed into the transplanted intestinal artery at a dose of 1000000 cells/kg. The second and third doses of MSCs were given directly into the mesenteric artery through the arterial anastomosis using an angiography catheter on day 15 and 30 post-transplant.

Results: The median follow-up for these patients was 10.6 mo (min: 2 mo-max: 30 mo). Three of the patients developed severe acute rejection. One of these patients did not respond to bolus steroid therapy. Although the other two patients did respond to anti-rejection treatment, they developed severe fungal and bacterial infections. All of these patients died in the 2(nd) and 3(rd) months post-transplant due to sepsis. The remaining patients who did not have acute rejection had good quality of life with no complications observed during the follow-up period. In addition, their intestinal grafts were functioning properly in the 13(th), 25(th) and 30(th) month post-transplant. The patients who survived did not encounter any problems related to MSC transplantation.

Conclusion: Although this is a small case series and not a randomized study, it is our opinion that small bowel transplantation is an effective treatment for intestinal failure, and MSC therapy may help to prevent acute rejection and graft vs host disease following intestinal transplantation.

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v20.i25.8215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081695PMC
July 2014
25 Reads

Publication Analysis

Top Keywords

acute rejection
16
small bowel
12
msc therapy
12
patients
9
host disease
8
disease intestinal
8
developed severe
8
bowel transplantation
8
graft host
8
therapy patients
8
mesenchymal stem
8
stem cell
8
mesenteric artery
8
patients respond
8
rejection graft
8
intestinal
6
therapy
5
three patients
4
fungal bacterial
4
patients developed
4

Similar Publications